Search Results - "Sverdlin, R."

Docetaxel–cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer by Spielmann, M., Llombart, A., Zelek, L., Sverdlin, R., Rixe, O., Le Cesne, A.

“…Purpose: The safety and efficacy of a docetaxel-cisplatin combination (DC) were evaluated in 41 patients pretreated for advanced breast cancer (ABC). Patients…”
Get full text

Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial by Falandry, Claire, Rousseau, Frédérique, Mouret-Reynier, Marie-Ange, Tinquaut, Fabien, Lorusso, Domenica, Herrstedt, Jørn, Savoye, Aude-Marie, Stefani, Laetitia, Bourbouloux, Emmanuelle, Sverdlin, Robert, D'Hondt, Veronique, Lortholary, Alain, Brachet, Pierre-Emmanuel, Zannetti, Alain, Malaurie, Emmanuelle, Venat-Bouvet, Laurence, Trédan, Olivier, Mourey, Loïc, Pujade-Lauraine, Eric, Freyer, Gilles

“…Single-agent carboplatin is often proposed instead of a conventional carboplatin-paclitaxel doublet in vulnerable older patients with ovarian cancer. Such an…”
Get more information

812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial by Colombo, N., Gantzer, J., Ataseven, B., Cropet, C., Scambia, G., Herrero, A., Sevelda, P., Kobayashi, H., Vuylsteke, P., Mirza, M.R., Priou, F., Buderath, P., Pisano, C., Lainez, N., Guillemet, C., Burges, A., Sverdlin, R., El-Balat, A., Raban, N., Ray-Coquard, I.L.

Get full text

Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): Treatment results and toxicity profile by Gholam, D., Giacchetti, S., Brezault Bonnet, C., Bouchahda, M., Sverdlin, R., Adam, R., Jasmin, C., Levi, F.

“…Abstract only…”
Get full text

Chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L), and oxaliplatin (O) (chrono IFLO) as salvage therapy in oxaliplatin- and irinotecan-resistant advanced colorectal cancer (ACRC): Treatment results and toxicity profile by Gholam, D., Giacchetti, S., Brezault Bonnet, C., Bouchahda, M., Sverdlin, R., Adam, R., Jasmin, C., Levi, F.

“…Abstract only…”
Get full text